Study directory

Anxiety studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
4175studies shown
Showing 1,237-1,248 of 4,175
Drug study icon
CompletedEUCTR 2004-002626-22

Duloxetine 60 to 120 mg Once Daily Compared with Placebo in the Prevention of Relapse in Generalized Anxiety Disorder

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria
Why is this study shown?

This study is directly about Anxiety.

AnxietyDrugA study involving a medication or substance.
Countries
Austria, Germany
Sponsor
Eli Lilly and Company Limited
Condition
Anxiety
Drug study icon
CompletedEUCTR 2012-001666-15

Efficacy and safety of 2 doses of agomelatine (10 mg/day or 25 mg/day) versus placebo given orally for 12 weeks in non depressed out-patients with Generalized Anxiety Disorder. A 12-week randomise...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Finland
Why is this study shown?

This study is directly about Anxiety.

AnxietyDrug
Countries
Finland, Poland, Slovakia
Sponsor
Institut de Recherches Internationales Servier
Condition
Anxiety
Drug study icon
TerminatedEUCTR 2008-003421-17

Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment at 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, dou...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Czech Republic
Why is this study shown?

This study is directly about Anxiety.

AnxietyDrug
Countries
Czechia, Slovakia
Sponsor
Institut de Recherches Internationales Servier
Condition
Anxiety
Drug study icon
CompletedEUCTR 2009-013789-17

Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment to 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, dou...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Czech Republic
Why is this study shown?

This study is directly about Anxiety.

AnxietyDrug
Countries
Czechia, Finland, Slovakia
Sponsor
Institut de Recherches Internationales Servier
Condition
Anxiety
Drug study icon
CompletedEUCTR 2005-004474-25

Multi-center, double-blind, placebo-controlled, randomized dose-finding study on Lavender oil WS 1265 (Lavandula angustifolia) in patients with generalized anxiety disorder

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany
Why is this study shown?

This study is directly about Anxiety.

AnxietyDrug
Countries
Germany
Sponsor
Dr. Willmar Schwabe GmbH & Co. KG
Condition
Anxiety
Drug study icon
CompletedEUCTR 2006-003597-10

Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Finland
Why is this study shown?

This study is directly about Anxiety.

AnxietyDrug
Countries
Finland, Germany, Sweden
Sponsor
GlaxoSmithKline Research & Development
Condition
Anxiety
Drug study icon
Recruitment unclearEUCTR 2015-003542-68

The effect of single-dose losartan on the basic effects of cognitive-behaviour therapy for panic disorder - a randomized double blind placebo-controlled trial

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
Why is this study shown?

This study is directly about Anxiety.

AnxietyDrug
Countries
United Kingdom
Sponsor
University of Oxford
Condition
Anxiety
Device study icon
Not recruitingISRCTN10661970

Investigating the efficacy of self-guided digital treatment with virtual reality for panic disorder and agoraphobia

This observational study is following people with Self-guided treatment for with panic disorder and agoraphobia or Mental and Behavioural Disorders to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.

In Germany
Why is this study shown?

This study is directly about Anxiety.

AnxietyOther
Countries
Germany
Sponsor
University of Siegen
Condition
Anxiety
Other study type icon
Not recruitingISRCTN30996662

Preventing early anxiety disorders

This study is looking at whether a parenting support programme can help people with Child internalising problems, Mental and Behavioural Disorders, or Other anxiety. Participants take part in a parenting support programme and complete follow-up assessments.

In Australia
Why is this study shown?

This study is directly about Anxiety.

AnxietyOther
Countries
Australia
Sponsor
National Health and Medical Research Council (NHMRC) (Australia)
Condition
Anxiety
Behavioral study icon
Not recruitingISRCTN18013983

Self-guided virtual reality therapy for social anxiety disorder

This study is looking at whether psychoeducation can help people with Self-guided treatment for with social anxiety or Mental and Behavioural Disorders. Participants take part in psychoeducation and complete follow-up assessments.

In Germany
Why is this study shown?

This study is directly about Anxiety.

AnxietyOther
Countries
Germany
Sponsor
University of Siegen
Condition
Anxiety
Drug study icon
CompletedNCT05729373

A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

This study is completed in the United States, in Bulgaria, in Estonia, .... It focuses on anxiety.

Multiple locations, including Huntsville
Why is this study shown?

This study is directly about Anxiety.

AnxietyDrugFrom 18 Years to 65 Years
Countries
United States, Bulgaria, Estonia, ...
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Anxiety
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.